Full video transcriptClick to expand
Auto-generated transcript of @my.journey.with.marc's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00This injection site completely changed the game from Yem and Jaro, so it's not the one
- 0:03everyone tells you to use, and before you copy me, stay to the end so you understand why
- 0:06this one helped me get my results. So my name is Mark and I've lost 9 stone or 57 kilos and just
- 0:11under Yem and Jaro and I'm sharing everything I wish someone had told me earlier from someone who
- 0:15has reached school and has now on maintenance. So follow along and see if this because I've got
- 0:19hundreds of GLP1 tips on my profile that can help you whether you're just starting,
- 0:22you're stuck, or maybe just dealing with really bad side effects. So I have tried every single
- 0:27injection site. The stomach, the arm, the leg, and for me, the leg was the one that felt the most
- 0:31consistent. My crevins felt steadier for your rough days, just less of that up and down feeling
- 0:37through the weeks. But the important part is this is my body, that's not a rule. So keep listening
- 0:42because this bit is really really important. If you're in your journey like me, you know,
- 0:45everything I use, I'm recommend from guides, the resources, it's all linked to my bio, so
- 0:48you're not figuring this out alone. So the biggest mistake people make is copying an injection
- 0:52site forever because somebody said it worked. Different sites can feel different for you,
- 0:56so the real key is testing them and paying attention to how you feel. So let me know,
- 1:00where do you inject right now? Have you ever tried switching or are you stuck in the same
- 1:03spot every time? I want to know. So drop it in the comments and yes, I'll catch you on the next one.
Mounjaro 'best site' claims on TikTok: what the data says
Quick answer
Tirzepatide (Mounjaro/Zepbound) is approved for subcutaneous injection into the abdomen, thigh, or upper arm, with rotation recommended to prevent lipohypertrophy and maintain consistent absorption. The creator's report of improved consistency after switching to thigh injection is anecdotally plausible, particularly if prior abdominal site overuse had caused tissue changes, but no head-to-head pharmacokinetic data for tirzepatide across injection sites exists in the published literature. Patients experiencing variable week-to-week response should discuss injection technique and site rotation with their prescribing clinician rather than self-adjusting based on social media protocols.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Mounjaro 'best site' claims on TikTok: what the data says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Mounjaro 'best site' claims on TikTok: what the data says" from My Journey with Marc. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide (Mounjaro/Zepbound) is approved for subcutaneous injection into the abdomen, thigh, or upper arm, with rotation recommended to prevent lipohypertrophy and maintain consistent absorption.
The reason this review is not generic is the source wording and the canonical claim label "glp1 the site that worked best for me on mounjaro fyp." In this clip, the useful excerpt is: "This injection site completely changed the game from Yem and Jaro, so it's not the one everyone tells you to use, and before you copy me, stay to the end so you understand why this one helped me get my results." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Tirzepatide (Mounjaro/Zepbound) is approved for subcutaneous injection into the abdomen, thigh, or upper arm, with rotation recommended to prevent lipohypertrophy and maintain consistent absorption.
FormBlends verdict
Compounded Tirzepatide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Tirzepatide (Mounjaro/Zepbound) is approved for subcutaneous injection into the abdomen, thigh, or upper arm, with rotation recommended to prevent lipohypertrophy and maintain consistent absorption. The creator's report of improved consistency after switching to thigh injection is anecdotally plausible, particularly if prior abdominal site overuse had caused tissue changes, but no head-to-head pharmacokinetic data for tirzepatide across injection sites exists in the published literature. Patients experiencing variable week-to-week response should discuss injection technique and site rotation with their prescribing clinician rather than self-adjusting based on social media protocols.
- Tirzepatide's prescribing information approves three injection sites (abdomen, thigh, upper arm) with no hierarchy, and rotation within and across sites is the clinical standard.
- Blanco et al. (2016, Diabetes Care) found lipohypertrophy can reduce subcutaneous drug absorption by up to 25 percent, which is a more likely explanation for variable weekly response than site location alone.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- Tirzepatide's prescribing information approves three injection sites (abdomen, thigh, upper arm) with no hierarchy, and rotation within and across sites is the clinical standard.
- Blanco et al. (2016, Diabetes Care) found lipohypertrophy can reduce subcutaneous drug absorption by up to 25 percent, which is a more likely explanation for variable weekly response than site location alone.
- A 2022 pharmacokinetic analysis of semaglutide (Davies et al., Diabetes, Obesity and Metabolism) found no statistically significant difference in peak plasma concentration between subcutaneous injection sites under controlled conditions.
- Mark's core message, test sites and observe your own response rather than copying someone else, is consistent with individualised clinical guidance and is not contradicted by current evidence.
- The video does not mention lipohypertrophy, which is the most clinically relevant reason injection sites stop performing consistently and the main thing viewers should actually check with their provider.
- Subjective reports of 'steadier cravings' cannot be attributed to site location without pharmacokinetic data, though the experience may reflect improved absorption after avoiding overused tissue.
- If your medication feels less effective week to week, discuss injection technique and site rotation with your prescriber before assuming the drug is not working.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @my.journey.with.marc actually say?
Mark claimed that switching his tirzepatide injection to his thigh gave him more consistent cravings control and less of the "up and down feeling" week to week. He was clear this was personal experience, not a rule, and he actively discouraged copying him without understanding why. He also told viewers to test sites and pay attention to how they feel, which is genuinely decent advice that a lot of creators skip over.
He framed this around a 57-kilogram weight loss on tirzepatide and presented himself as someone now in maintenance. He didn't claim the thigh works for everyone, and he didn't prescribe a dose or protocol. That restraint matters and is worth noting upfront before we get into what the evidence actually says.
Does the science back this up?
Partially, yes. The idea that injection site affects drug absorption is not invented, but the evidence is messier than most people realise, and tirzepatide-specific data is thin.
A 2014 review by Heise et al. in Diabetes Technology and Therapeutics found meaningful differences in insulin absorption rates between abdomen, thigh, and arm sites, with the abdomen generally showing faster uptake. For GLP-1 receptor agonists, the picture is less clear. A 2022 pharmacokinetic analysis of semaglutide in Diabetes, Obesity and Metabolism found no statistically significant difference in peak plasma concentration between subcutaneous sites in a controlled setting. However, real-world variables like tissue composition, lipohypertrophy from repeated injections, and individual body fat distribution can all shift absorption in ways a controlled trial won't capture.
Mark's reported subjective experience of steadier cravings from thigh injection is biologically plausible if he had developed lipohypertrophy at his abdominal sites from months of injections to the same area. Injecting into hardened tissue genuinely does blunt absorption. So his switch may have fixed that problem rather than the thigh being inherently superior.
What did they get wrong (or right)?
Mark got the core message right. He was right that injection sites can behave differently for different people. He was right that copying someone else's site without testing your own response is not a good strategy. And he was right to say this is about his body, not a universal rule.
What he didn't address, and this is the real gap in the video, is lipohypertrophy. This is the most clinically important reason to rotate sites and it goes completely unmentioned. If viewers hear "try the thigh" and then inject the same thigh spot every week, they have learned nothing useful. The lesson isn't which site, it's that rotation within and across sites matters enormously for consistent absorption.
He also used the word "cravings" in a way that conflates multiple mechanisms. Tirzepatide's appetite effects come from GIP and GLP-1 receptor dual agonism centrally and peripherally. Whether a subcutaneous depot in the thigh versus abdomen meaningfully alters that signalling over a weekly dosing window is not something the current evidence supports as a firm conclusion. His experience is real. The mechanistic explanation he implies is speculative.
What should you actually know?
Injection site rotation is not optional, it is a basic clinical requirement for any injectable medication given subcutaneously long-term. The American Diabetes Association recommends rotating within a region and across regions to prevent lipohypertrophy, a condition where fatty lumps form under the skin and can reduce drug absorption by up to 25 percent according to a 2016 study by Blanco et al. in Diabetes Care.
The approved sites for tirzepatide per the Zepbound and Mounjaro prescribing information are the abdomen, thigh, and upper arm. No site is listed as superior. Your prescriber or pharmacist is the right person to help you troubleshoot absorption issues, not a TikTok comment section.
If you feel like your medication stopped working or your week-to-week response is unpredictable, lipohypertrophy is one of the first things worth discussing with your provider, not just which site you use. Mark's instinct to switch and pay attention was correct. The explanation for why it helped him is more complicated than the video suggests.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
My Journey with Marc · TikTok creator
121.2K views on this video
The site that worked best for me on #Mounjaro! #FYP
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about tirzepatide's prescribing information approves three injection sites (abdomen, thigh, upper?
Tirzepatide's prescribing information approves three injection sites (abdomen, thigh, upper arm) with no hierarchy, and rotation within and across sites is the clinical standard.
What does the video say about blanco et al. (2016, diabetes care) found lipohypertrophy can reduce?
Blanco et al. (2016, Diabetes Care) found lipohypertrophy can reduce subcutaneous drug absorption by up to 25 percent, which is a more likely explanation for variable weekly response than site location alone.
What does the video say about a 2022 pharmacokinetic analysis of semaglutide (davies et al., diabetes,?
A 2022 pharmacokinetic analysis of semaglutide (Davies et al., Diabetes, Obesity and Metabolism) found no statistically significant difference in peak plasma concentration between subcutaneous injection sites under controlled conditions.
What does the video say about mark's core message, test sites?
Mark's core message, test sites and observe your own response rather than copying someone else, is consistent with individualised clinical guidance and is not contradicted by current evidence.
What does the video say about the video does not mention lipohypertrophy,?
The video does not mention lipohypertrophy, which is the most clinically relevant reason injection sites stop performing consistently and the main thing viewers should actually check with their provider.
What does the video say about subjective reports of 'steadier cravings' cannot be attributed to site?
Subjective reports of 'steadier cravings' cannot be attributed to site location without pharmacokinetic data, though the experience may reflect improved absorption after avoiding overused tissue.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by My Journey with Marc, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.